Showing 20 of 68 recruiting trials for “t-cell-non-hodgkin-lymphoma”
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
🏥 Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Dec 2024View details ↗
SynKIR-310 for Relapsed/Refractory B-NHL
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
RecruitingNCT06550427 ↗
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
👨⚕️ Tai-Chung Huang, Ph.D, National Taiwan University Hospital📍 1 site📅 Started Aug 2024View details ↗
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
👨⚕️ Breffni Hannon, MB BCh BAO, MMedSci, MCFP, Princess Margaret Cancer Centre📍 1 site📅 Started Jul 2024View details ↗
RecruitingNCT06796517 ↗
Immunotherapy in Lymphoma
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
👨⚕️ Catherine THIEBLEMONT, Prof. Dr., Hôpital Saint-Louis📍 13 sites📅 Started Jun 2024View details ↗
RecruitingNCT06497452 ↗
A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma
👨⚕️ Qingqing Cai, Ph D, Sun Yat-Sen University Cancer Center📍 1 site📅 Started Apr 2024View details ↗
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
👨⚕️ Grzegorz S Nowakowski, Academic and Community Cancer Research United📍 6 sites📅 Started Jan 2024View details ↗
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
👨⚕️ Wei Liu, Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC📍 1 site📅 Started Jan 2024View details ↗
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
👨⚕️ Yuqin Song, M.D, Peking University Cancer Hospital & Institute📍 1 site📅 Started Dec 2023View details ↗
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →